Status:
UNKNOWN
11C-Acetate PET/CT Non-FDG-Avid Tumors
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Soft Tissue Sarcomas
Thyroid Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are v...
Detailed Description
Recent publications have suggested the use of 11C-acetate as another PET tracer for tumor imaging. The accumulation of 11C-acetate in tumor cells is related to the highly active lipid metabolism in th...
Eligibility Criteria
Inclusion
- patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake:
- Soft tissue sarcomas
- well-differentiated thyroid cancer
- well-differentiated and bronchoalveolar lung cancer
- indolent lymphomas
- neuroendocrine tumors
- GIST
- uterine malignancies
- mucin-producing cancer
- teratoma
- hepatoma
- HCC
- lobular breast carcinoma
- Patients over the age of 18
Exclusion
- patients under the age of 18 years
- pregnant and lactating women
- claustrophobic patients
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00687778
Start Date
May 1 2008
End Date
June 1 2010
Last Update
June 2 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239